HC Wainwright & Co. Reiterates Buy on Cidara Therapeutics, Maintains $24 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce has reiterated a Buy rating for Cidara Therapeutics (NASDAQ:CDTX) and maintained a price target of $24.
September 16, 2024 | 10:35 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Ed Arce has reiterated a Buy rating for Cidara Therapeutics and maintained a price target of $24, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $24 price target by a reputable analyst suggests a positive outlook for Cidara Therapeutics. This could lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100